- Home
- EML vs AARD Comparison
EML vs AARD Comparison
Compare EML & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- AARD
- Stock Information
- Founded
- EML 1858
- AARD 2017
- Country
- EML United States
- AARD United States
- Employees
- EML N/A
- AARD N/A
- Industry
- EML Industrial Machinery/Components
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- AARD Health Care
- Exchange
- EML Nasdaq
- AARD Nasdaq
- Market Cap
- EML 130.9M
- AARD 154.9M
- IPO Year
- EML N/A
- AARD 2025
- Fundamental
- Price
- EML $22.01
- AARD $11.13
- Analyst Decision
- EML
- AARD Strong Buy
- Analyst Count
- EML 0
- AARD 4
- Target Price
- EML N/A
- AARD $31.25
- AVG Volume (30 Days)
- EML 9.3K
- AARD 42.7K
- Earning Date
- EML 05-06-2025
- AARD 05-14-2025
- Dividend Yield
- EML 1.97%
- AARD N/A
- EPS Growth
- EML N/A
- AARD N/A
- EPS
- EML N/A
- AARD N/A
- Revenue
- EML $271,440,503.00
- AARD N/A
- Revenue This Year
- EML $6.05
- AARD N/A
- Revenue Next Year
- EML $7.00
- AARD N/A
- P/E Ratio
- EML $10.66
- AARD N/A
- Revenue Growth
- EML 8.15
- AARD N/A
- 52 Week Low
- EML $19.06
- AARD $4.88
- 52 Week High
- EML $35.03
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- EML 44.17
- AARD N/A
- Support Level
- EML $22.60
- AARD N/A
- Resistance Level
- EML $23.11
- AARD N/A
- Average True Range (ATR)
- EML 0.71
- AARD 0.00
- MACD
- EML -0.09
- AARD 0.00
- Stochastic Oscillator
- EML 4.68
- AARD 0.00
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.